Cold-induced Brown Fat Activation and Hepatic Steatosis

NCT ID: NCT03811236

Last Updated: 2024-03-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-21

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the recent years, research on brown adipose tissue (BAT) revealed that larger amounts as well as higher activity thereof are associated with a favourable metabolic phenotype. Longitudinal studies which applied recurrent cooling sessions demonstrated a high plasticity of BAT which significantly increased in size and activity during these studies. These changes were accompanied by improvements in body fat mass as well as insulin sensitivity. Non-alcoholic fatty liver disease (NAFLD) is estimated to advance to the primary cause of liver cirrhosis and hepatocellular carcinoma in the following years. Besides predisposing genetic and possibly nutritional factors, the insulin resistance syndrome and obesity are the main factors contributing to this excessive hepatic lipid accumulation.

The aim of this study is to investigate whether BAT recruitment via cold-acclimation results in decreased hepatic lipid content in overweight/obese patients with NAFLD.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Alcoholic Fatty Liver Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cold exposure

Group Type EXPERIMENTAL

Cold exposure

Intervention Type OTHER

Two hours of mild cold exposure using a water-perfused vest

Room temperature

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cold exposure

Two hours of mild cold exposure using a water-perfused vest

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* body mass index 28 - 40 kg/m\^2
* hepatic lipid content \> 10 %

Exclusion Criteria

* endocrine disease, except treated hypo-/hyperthyroidism and hypertriglyceridemia (\<500 mg/dl) and untreated type II diabetes mellitus (fasting glucose \< 140 mg/dl)
* use of beta-blockers, alpha-blockers and rilmenidine
* chronic kidney disease
* inflammatory bowel disease
* active malignant disease
* autoimmune disease
* chronic alcohol abuse or alcohol consumption greater than 30g/d for men or 20 g/d for women
* transferrin saturation \> 40%
* serum alpha-1 antitrypsin \< 90 mg/dl
* serum ceruloplasmin \< 20 mg/dl
* positive serology for autoimmune hepatitis
* positive hepatitis serology
* liver cirrhosis
* portal hypertension
* pregnancy
* contraindications for magnetic resonance imaging
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medical University of Vienna

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. Florian Kiefer

Associate Professor of Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Florian Kiefer, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Medical University of Vienna

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical University of Vienna

Vienna, , Austria

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Austria

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Florian Kiefer, MD, PhD

Role: CONTACT

+43140400 ext. 43120

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Florian Kiefer, MD, PhD

Role: primary

+43140400 ext. 43120

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1911/2017

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Inuit and Cold Exposure
NCT05884177 RECRUITING
Cryotherapy and Body Slimming
NCT04287153 COMPLETED NA
Cooling in Myocardial Infarction
NCT01777750 COMPLETED NA